Zhaoqing Cong

Dr. Zhaoqing Cong

Department of Biochemistry and Molecular Medicine, University of California Davis, Sacramento, CA 95817, USA
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2020 in Nature Nanotechnology
Verified
Journal Article
Closed access
PDF file
LZLu Zhang
Lu Zhang
DJDi Jing
Di Jing
NJNian Jiang
Nian Jiang
TRTatu Rojalin
Tatu Rojalin
CBChristopher M. Baehr
Christopher M. Baehr
KLKit S. Lam
Kit S. Lam

5 February 2020 in ACS Nano
Verified
Journal Article
Closed access
Zhaoqing CongZhaoqing Cong
Zhaoqing Cong
LZLu Zhang
Lu Zhang
SMSi-Qi Ma
Si-Qi Ma
KLKit S. Lam
Kit S. Lam
FYFei-Fei Yang
Fei-Fei Yang
YLYonghong Liao
Yonghong Liao

27 May 2022 in Advanced Materials
Verified
Journal Article
Closed access
Zhaoqing CongZhaoqing Cong
Zhaoqing Cong
STSongsong Tang
Songsong Tang
LXLeiming Xie
Leiming Xie
MYMing Yang
Ming Yang
YLYangyang Li
Yangyang Li
SWSong Wu
Song Wu

9 June 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
PTPhonpilas Thongpon
Phonpilas Thongpon
MTMenghuan Tang
Menghuan Tang
Zhaoqing CongZhaoqing Cong
Zhaoqing Cong
Cancer treatment continues to face significant challenges due to the limitations of conventional therapies, including non-specific toxicity, poor bioavailability, and drug resistance. Nanotechnology, particularly peptide-based nanoparticles (NPs), is increasingly recognized as a valuable strategy to address these obstacles. Peptides provide a versatile platform offering high biocompatibility, specificity, biodegradability, and minimal immunogenicity, making them ideal for targeted cancer therapies. This review comprehensively examines recent advancements in peptide-based nanoparticle systems, highlighting the mechanisms driving peptide self-assembly, such as amphiphilicity, non-covalent interactions, and metal coordination. It distinguishes between non-bioactive peptide nanoparticles, which primarily serve as drug carriers, and bioactive peptide nanoparticles, which integrate targeting peptides, cell-penetrating peptides (CPPs), and therapeutic peptides to enhance specificity, internalization, and anticancer efficacy. Emphasis is placed on innovative designs that exploit active targeting, stimuli-responsive release, and immunomodulatory strategies to maximize therapeutic outcomes while minimizing side effects. Despite promising preclinical outcomes, the clinical translation of peptide nanoparticles struggles with challenges involving stability, delivery efficiency, scalability, regulatory compliance, and manufacturing complexity. The review concludes by outlining future directions, emphasizing personalized nanomedicine, combination therapies, and advanced peptide engineering as crucial pathways toward successful clinical implementation.

10 June 2023 in Small
Verified
Journal Article
Closed access
YLYangyang Li
Yangyang Li
Zhaoqing CongZhaoqing Cong
Zhaoqing Cong
LXLeiming Xie
Leiming Xie
STSongsong Tang
Songsong Tang
CRChunyu Ren
Chunyu Ren
SWSong Wu
Song Wu

3 December 2021 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
QCQiwei Chen
Qiwei Chen
STSongsong Tang
Songsong Tang
YLYangyang Li
Yangyang Li
Zhaoqing CongZhaoqing Cong
Zhaoqing Cong
DLDongdong Lu
Dongdong Lu
SWSong Wu
Song Wu